Imagine Eyes enters a new distribution partnership with Chuo Sangio Co. in Japan
March 21, 2017, Orsay, France, and Nishinomiya, Japan . Imagine Eyes® has signed an exclusive distribution agreement with Chuo Sangio Co. to sell its rtx1-e Adaptive Optics Retinal Camera in Japan.
“Imagine Eyes’ rtx1-e product allows doctors to easily acquire ultra-high resolution retinal images that no other technology can provide”, says Chuo Sangio Co.’s President and CEO Kazuo Kuwahara. This device uses the most advanced adaptive optics technology. We firmly believe that its introduction to the Japanese market will make a great contribution to early detection of diseases in a perspective of preventive medicine.”
“In addition to its strong position in the market, Chuo Sangio Co. combines multiple advantages including irreproachable reputation for service, high expertise in retinal imaging, and excellent relational skills,” said Imagine Eyes’ CEO Nicolas Chateau. “There is no doubt that this partnership is a major milestone in the deployment of our technology in Japan.”
Imagine Eyes is a recognized pioneer in ultrahigh-resolution retinal imaging. Its breakthrough products enable doctors to examine the back of the eye with unprecedented detail, in order to detect early signs of diseases and better adapt treatments to patients. Such unique performance is provided by adaptive optics, a technology derived from astrophysics.
Chuo Sangio Co. has been importing and distributing ophthalmic medical devices in Japan for nearly 90 years. The company’s mission is to discover manufacturers of leading-edge diagnostic and surgical instruments from all over the world, and introduce their high-technology products to the Japanese market. Chuo Sangio Co. has gained the trust of Japanese doctors, while contributing to eye health, quality of vision and quality of life.
In February, Chuo Sangio Co. and Imagine Eyes submitted a Shonin application to Japan’s Pharmaceuticals and Medical Devices Agency for approval of the rtx1-e Adaptive Optics Retinal Camera. Both partners anticipate commercialization in the second quarter of 2017. Chuo Sangio plans to exhibit the product for the first time at the Annual Meeting of Japanese Ophthalmological Society, on April 6-8, 2017 in Tokyo.
Click here to learn more about Imagine Eyes.
Click here to learn more about Chuo Sangio Co.